{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:40:10Z","timestamp":1721068810566},"reference-count":155,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2019,12,16]]},"abstract":"<jats:sec><jats:title\/><jats:p>Sexually Transmitted Diseases (STDs) refer to a variety of clinical syndromes and infections caused by pathogens that can be acquired and transmitted through sexual activity. Among STDs widely reported in the literature, viral sexual diseases have been increasing in a number of cases globally. This emphasizes the need for prevention and treatment. Among the methods widely used in drug planning are Computer-Aided Drug Design (CADD) studies and molecular docking which have the objective of investigating molecular interactions between two molecules to better understand the three -dimensional structural characteristics of the compounds. This review will discuss molecular docking studies applied to viral STDs, such as Ebola virus, Herpes virus and HIV, and reveal promising new drug candidates with high levels of specificity to their respective targets.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389203720666190311142747","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T10:54:03Z","timestamp":1552301643000},"page":"1135-1150","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Silico Studies against Viral Sexually Transmitted Diseases"],"prefix":"10.2174","volume":"20","author":[{"given":"Alex F.M.","family":"Monteiro","sequence":"first","affiliation":[{"name":"Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Para\u00edba, Joao Pessoa-PB, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessika","family":"de Oliveira Viana","sequence":"additional","affiliation":[{"name":"Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Para\u00edba, Joao Pessoa-PB, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engene","family":"Muratov","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Modeling, Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina, Beard Hall 301, CB#7568, Chapel Hill, NC, 27599, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus T.","family":"Scotti","sequence":"additional","affiliation":[{"name":"Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Para\u00edba, Joao Pessoa-PB, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Scotti","sequence":"additional","affiliation":[{"name":"Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Para\u00edba, Joao Pessoa-PB, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","DOI":"10.1002\/9781119380924","author":"Singh S.K.","year":"2018","unstructured":"Singh S.K.; Diagnostics to Pathogenomics of Sexually Trans-mitted Infections 2018","journal-title":"Diagnostics to Pathogenomics of Sexually Trans-mitted Infections"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","volume":"40","author":"Satterwhite C.L.","year":"2013","unstructured":"Satterwhite C.L.; Torrone E.; Meites E.; Dunne E.F.; Mahajan R.; Ocfemia M.C.B.; Su J.; Xu F.; Weinstock H.; Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013,40(3),187-193","journal-title":"Sex Transm Dis"},{"key":"ref=3","year":"2018","unstructured":"World Health Organization: Sexually transmitted infections 2016 (Accessed Set 15, 2018"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/OLQ.0000000000000286","volume":"43","author":"Friedman A.L.","year":"2016","unstructured":"Friedman A.L.; Kachur R.E.; Noar S.M.; McFarlane M.; Health communication and social marketing campaigns for sexually transmitted disease prevention and control: What is the evidence of their effectiveness? Sex Transm Dis 2016,43(2)(Suppl. 1),S83-S101","journal-title":"Sex Transm Dis"},{"key":"ref=5","year":"2018","unstructured":"Center of Disease Control: Sexually transmitted diseases treatment guidelines, 2010. (Accessed Set 15, 2018"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"Ferreira L.G.","year":"2015","unstructured":"Ferreira L.G.; Dos Santos R.N.; Oliva G.; Andricopulo A.D.; Molecular docking and structure-based drug design strategies. Molecules 2015,20(7),13384-13421","journal-title":"Molecules"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio.155","volume":"5","author":"Chen Y.","year":"2009","unstructured":"Chen Y.; Shoichet B.K.; Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 2009,5(5),358-364","journal-title":"Nat Chem Biol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"Kitchen D.B.","year":"2004","unstructured":"Kitchen D.B.; Decornez H.; Furr J.R.; Bajorath J.; Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004,3(11),935-949","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/jm0203783","volume":"46","author":"Wang R.","year":"2003","unstructured":"Wang R.; Lu Y.; Wang S.; Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 2003,46(12),2287-2303","journal-title":"J Med Chem"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","volume":"49","author":"Warren G.L.","year":"2006","unstructured":"Warren G.L.; Andrews C.W.; Capelli A.M.; Clarke B.; LaLonde J.; Lambert M.H.; Lindvall M.; Nevins N.; Semus S.F.; Senger S.; Tedesco G.; Wall I.D.; Woolven J.M.; Peishoff C.E.; Head M.S.; A critical assessment of docking programs and scoring functions. J Med Chem 2006,49(20),5912-5931","journal-title":"J Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1006\/jmbi.1996.0477","volume":"261","author":"Rarey M.","year":"1996","unstructured":"Rarey M.; Kramer B.; Lengauer T.; Klebe G.; A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996,261(3),470-489","journal-title":"J Mol Biol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","volume":"267","author":"Jones G.","year":"1997","unstructured":"Jones G.; Willett P.; Glen R.C.; Leach A.R.; Taylor R.; Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997,267(3),727-748","journal-title":"J Mol Biol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/prot.10028","volume":"46","author":"\u00d6sterberg F.","year":"2002","unstructured":"\u00d6sterberg F.; Morris G.M.; Sanner M.F.; Olson A.J.; Goodsell D.S.; Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002,46(1),34-40","journal-title":"Proteins"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1093-3263(02)00164-X","volume":"21","author":"Venkatachalam C.M.","year":"2003","unstructured":"Venkatachalam C.M.; Jiang X.; Oldfield T.; Waldman M.; LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003,21(4),289-307","journal-title":"J Mol Graph Model"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/jm020406h","volume":"46","author":"Jain A.N.","year":"2003","unstructured":"Jain A.N.; Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003,46(4),499-511","journal-title":"J Med Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bip.10207","volume":"68","author":"McGann M.R.","year":"2003","unstructured":"McGann M.R.; Almond H.R.; Nicholls A.; Grant J.A.; Brown F.K.; Gaussian docking functions. Biopolymers 2003,68(1),76-90","journal-title":"Biopolymers"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"Friesner R.A.","year":"2004","unstructured":"Friesner R.A.; Banks J.L.; Murphy R.B.; Halgren T.A.; Klicic J.J.; Mainz D.T.; Repasky M.P.; Knoll E.H.; Shelley M.; Perry J.K.; Shaw D.E.; Francis P.; Shenkin P.S.; Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004,47(7),1739-1749","journal-title":"J Med Chem"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10822-012-9570-1","volume":"26","author":"Corbeil C.R.","year":"2012","unstructured":"Corbeil C.R.; Williams C.I.; Labute P.; Variability in docking success rates due to dataset preparation. J Comput Aided Mol Des 2012,26(6),775-786","journal-title":"J Comput Aided Mol Des"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1016\/j.bmcl.2013.08.009","volume":"23","author":"Zhao H.","year":"2013","unstructured":"Zhao H.; Caflisch A.; Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. Bioorg Med Chem Lett 2013,23(20),5721-5726","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcc.23905","volume":"36","author":"Allen W.J.","year":"2015","unstructured":"Allen W.J.; Balius T.E.; Mukherjee S.; Brozell S.R.; Moustakas D.T.; Lang P.T.; Case D.A.; Kuntz I.D.; Rizzo R.C.; DOCK 6: Impact of new features and current docking performance. J Comput Chem 2015,36(15),1132-1156","journal-title":"J Comput Chem"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1039\/C6CP01555G","volume":"18","author":"Wang Z.","year":"2016","unstructured":"Wang Z.; Sun H.; Yao X.; Li D.; Xu L.; Li Y.; Tian S.; Hou T.; Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys 2016,18(18),12964-12975","journal-title":"Phys Chem Chem Phys"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/438575a","volume":"438","author":"Leroy E.M.","year":"2005","unstructured":"Leroy E.M.; Kumulungui B.; Pourrut X.; Rouquet P.; Hassanin A.; Yaba P.; D\u00e9licat A.; Paweska J.T.; Gonzalez J.P.; Swanepoel R.; Fruit bats as reservoirs of Ebola virus. Nature 2005,438(7068),575-576","journal-title":"Nature"},{"key":"ref=25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1409858","volume":"371","author":"Briand S.","year":"2014","unstructured":"Briand S.; Bertherat E.; Cox P.; Formenty P.; Kieny M.P.; Myhre J.K.; Roth C.; Shindo N.; Dye C.; The International Ebola Emergency. N Engl J Med (Accessed May 23, 2004)2014,371","journal-title":"N Engl J Med"},{"key":"ref=26","year":"2016","unstructured":"World Health Organization: Ebola situation report (Accessed Oct 9, 2018).2016","journal-title":"Ebola situation report"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/514308","volume":"179","author":"Bwaka M.A.","year":"1999","unstructured":"Bwaka M.A.; Bonnet M.J.; Calain P.; Colebunders R.; De Roo A.; Guimard Y.; Katwiki K.R.; Kibadi K.; Kipasa M.A.; Kuvula K.J.; Mapanda B.B.; Massamba M.; Mupapa K.D.; Muyembe-Tamfum J.J.; Ndaberey E.; Peters C.J.; Rollin P.E.; Van den Enden E.; Van den Enden E.; Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999,179(Suppl. 1),S1-S7","journal-title":"J Infect Dis"},{"key":"ref=28","year":"2014","unstructured":"Centers for Disease Control and Prevention: Transmission Of Ebola (Ebola Virus Disease), (Accessed Sep 18, 2018)2014"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3201\/eid0910.020493","volume":"9","author":"Hewlett B.S.","year":"2003","unstructured":"Hewlett B.S.; Amola R.P.; Cultural contexts of Ebola in northern Uganda. Emerg Infect Dis 2003,9(10),1242-1248","journal-title":"Emerg Infect Dis"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1086\/514291","volume":"179","author":"Rodriguez L.L.","year":"1999","unstructured":"Rodriguez L.L.; De Roo A.; Guimard Y.; Trappier S.G.; Sanchez A.; Bressler, Williams, D.A.J.; Rowe, A.K.; Bertolli, J.; Khan, A.S.; Ksiazek, T.G.; Peters, C.J.; Nichol, S.T. Persis-tence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999,179,170-176","journal-title":"J Infect Dis"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/QCO.0000000000000135","volume":"28","author":"Rogstad K.E.","year":"2015","unstructured":"Rogstad K.E.; Tunbridge A.; Ebola virus as a sexually transmitted infection. Curr Opin Infect Dis 2015,28(1),83-85","journal-title":"Curr Opin Infect Dis"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","volume":"377","author":"Deen G.F.","year":"2017","unstructured":"Deen G.F.; Broutet N.; Xu W.; Knust B.; Sesay F.R.; McDonald S.L.; Ervin E.; Marrinan J.E.; Gaillard P.; Habib N.; Liu H.; Liu W.; Thorson A.E.; Yamba F.; Mas-saquoi T.A.; James F.; Ariyarajah A.; Ross C.; Bernstein K.; Coursier A.; Klena J.; Carino M.; Wurie A.H.; Zhang Y.; Dumbuya M.S.; Abad N.; Idriss B.; Wi T.; Bennett S.D.; Davies T.; Ebrahim F.K.; Meites E.; Naidoo D.; Smith S.J.; Ongpin P.; Malik T.; Banerjee A.; Erickson B.R.; Liu Y.; Liu Y.; Xu, K.; Brault, A.; Durski, K.N.; Winter, J.; Sealy, T.; Nichol S.T.; Lamunu, M.; Bangura, J.; Landoulsi, S.; Jambai, A.; Morgan, A.; Wu, G.; Liang, M.; Su, Q.; Lan, Y.; Hao, Y.; Formenty, P.; Str\u00f6her, U.; Sahr, F. Ebola RNA persistence in semen of Ebola virus disease survivors. N Engl J Med 2017,377(15),1428-1437","journal-title":"N Engl J Med"},{"key":"ref=33","first-page":"479","volume":"64","author":"Christie A.","year":"2015","unstructured":"Christie A.; Davies-Wayne G.J.; Cordier-Lassalle T.; Blackley D.J.; Laney A.S.; Williams D.E.; Shinde S.A.; Badio M.; Lo T.; Mate S.E.; Ladner J.T.; Wiley M.R.; Kugelman J.R.; Palacios G.; Holbrook M.R.; Janosko K.B.; de Wit E.; van Doremalen N.; Munster V.J.; Pettitt J.; Schoepp R.J.; Verhenne L.; Evlampidou I.; Kollie K.K.; Sieh S.B.; Gasasira A.; Bolay F.; Kateh F.N.; Nyenswah T.G.; De Cock K.M.; Possible sexual transmission of Ebola virus - Liberia, 2015. MMWR Morb Mortal Wkly Rep 2015,64(17),479-481","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=34","year":"2018","unstructured":"World Health Organization. Interim advice on the sexual transmission of the Ebola virus disease, 2016. (Accessed Set 21, 2018"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","volume":"373","author":"Mate S.E.","year":"2015","unstructured":"Mate S.E.; Kugelman J.R.; Nyenswah T.G.; Ladner J.T.; Wiley M.R.; Cordier-Lassalle T.; Christie A.; Schroth G.P.; Gross S.M.; Davies-Wayne G.J.; Shinde S.A.; Murugan R.; Sieh S.B.; Badio M.; Fakoli L.; Taweh F.; de Wit E.; van Doremalen N.; Munster V.J.; Pettitt J.; Prieto K.; Humrighouse B.W.; Str\u00f6her U.; DiClaro J.W.; Hensley L.E.; Schoepp R.J.; Safronetz D.; Fair J.; Kuhn J.H.; Blackley D.J.; Laney A.S.; Williams D.E.; Lo T.; Gasasira A.; Nichol S.T.; Formenty P.; Kateh F.N.; De Cock K.M.; Bolay F.; Sanchez-Lockhart M.; Palacios G.; Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 2015,373(25),2448-2454","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/v7020511","volume":"7","author":"Judson S.","year":"2015","unstructured":"Judson S.; Prescott J.; Munster V.; Understanding ebola virus transmission. Viruses 2015,7(2),511-521","journal-title":"Viruses"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1126\/science.1259657","volume":"345","author":"Gire S.K.","year":"2014","unstructured":"Gire S.K.; Goba A.; Andersen K.G.; Sealfon R.S.G.; Park D.J.; Kanneh L.; Jalloh, s.; Momoh, M.; Fullah, M.; Dudas, G.; Wohl, S.; Moses, L.M.; Yozwiak, N.L.; Winnicki, S.; Matranga, C.B.; Malboeyf, C.M.; Qu, J.; Glandden, A.D.; Schaffner, S.F.; Yang, X.; Jiang, P.P.; Nekoui, M.; Colubri, A.; Coomber, M.R.; Fonnie, M.; Moigboi, A.; Gbakie, M.; Kama-ra, F.K.; Tucker, V.; Konuwa, E.; Saffa, S.; Sellu, J.; Jalloh, A.A.; Jovoma, A.; Koninga, J.; Mustapha, I.; Kargbo, K.; Fo-day, M.; Yillah, M.; Kanneh, F.; Robert, W.; Massally, J.L.B.; Chapman, S.B.; Bochicchio, J.; Murphy, C.; Nusbaum, C.; Young, S.; Birren, B.W.; Grant, D.S.; Scheiffelin, J.S.; Lander, E.S.; Happi, C.; Gevao, S.M.; Gnirke, A.; Rambaut, A.; Garry, R.F.; Khan, S.H.; Sabeti, P.C. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 out-break. Science 2014,345,1369-1372","journal-title":"Science"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"D576","DOI":"10.1093\/nar\/gkq901","volume":"39","author":"Hulo C.","year":"2011","unstructured":"Hulo C.; de Castro E.; Masson P.; Bougueleret L.; Bairoch A.; Xenarios I.; Le Mercier P.; ViralZone: A knowledge resource to understand virus diversity. Nucleic Acids Res 2011,39(Database issue),D576-D582","journal-title":"Nucleic Acids Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/srep01206","volume":"3","author":"Nanbo A.","year":"2013","unstructured":"Nanbo A.; Watanabe S.; Halfmann P.; Kawaoka Y.; The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Sci Rep 2013,3,1206","journal-title":"Sci Rep"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12539-015-0109-8","volume":"8","author":"Raj U.","year":"2016","unstructured":"Raj U.; Varadwaj P.K.; Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: In silico discovery using virtual screening and molecular docking studies. Interdiscip Sci 2016,8(2),132-141","journal-title":"Interdiscip Sci"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1573406411666141229162834","volume":"11","author":"Chou K.C.","year":"2015","unstructured":"Chou K.C.; Impacts of bioinformatics to medicinal chemistry. Med Chem 2015,11(3),218-234","journal-title":"Med Chem"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","volume":"167","author":"Diehl W.E.","year":"2016","unstructured":"Diehl W.E.; Lin A.E.; Grubaugh N.D.; Carvalho L.M.; Kim K.; Kyawe P.P.; McCauley S.M.; Donnard E.; Kucukural A.; McDonel P.; Schaffner S.F.; Garber M.; Rambaut A.; Andersen K.G.; Sabeti P.C.; Luban J.; Ebola virus glycopro-tein with increased infectivity dominated the 2013-2016 epi-demic. Cell 2016,167(4),1088-1098.e6","journal-title":"Cell"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1097-2765(00)80159-8","volume":"2","author":"Weissenhorn W.","year":"1998","unstructured":"Weissenhorn W.; Carf\u00ed A.; Lee K.H.; Skehel J.J.; Wiley D.C.; Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 1998,2(5),605-616","journal-title":"Mol Cell"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","volume":"94","author":"Takada A.","year":"1997","unstructured":"Takada A.; Robison C.; Goto H.; Sanchez A.; Murti K.G.; Whitt M.A.; Kawaoka Y.; A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997,94(26),14764-14769","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/3-540-26764-6_2","volume":"Vol. 285","author":"Earp L.J.","year":"2004","unstructured":"Earp L.J.; Delos S.E.; Park H.E.; White J.M.; Mem-brane trafficking in viral replication 2004,Vol. 285,25-66","journal-title":"Mem-brane trafficking in viral replication"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","volume":"347","author":"Sakurai Y.","year":"2015","unstructured":"Sakurai Y.; Kolokoltsov A.A.; Chen C.C.; Tidwell M.W.; Bauta W.E.; Klugbauer N.; Grimm C.; Wahl-Schott C.; Biel M.; Davey R.A.; Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 2015,347(6225),995-998","journal-title":"Science"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"Lee J.E.","year":"2008","unstructured":"Lee J.E.; Fusco M.L.; Hessell A.J.; Oswald W.B.; Burton D.R.; Saphire E.O.; Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008,454(7201),177-182","journal-title":"Nature"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jmgm.2016.12.010","volume":"72","author":"Ahmad N.","year":"2017","unstructured":"Ahmad N.; Farman A.; Badshah S.L.; Ur Rahman A.; Ur Rashid H.; Khan K.; Molecular modeling, simulation and docking study of ebola virus glycoprotein. J Mol Graph Model 2017,72,266-271","journal-title":"J Mol Graph Model"},{"key":"ref=49","first-page":"211","volume":"5","author":"Shinyguruce A.","year":"2018","unstructured":"Shinyguruce A.; Sathya D.; Keerthiga K.; Pavithra P.; Vin-itha M.; Vaidheeswari R.; Eswara P.B.; In Silico Antiviral Drug Screening and Molecular Docking Studies Against Ebola Virus Glycoprotein. J Appl Sci Comput 2018,5(9),211-216","journal-title":"J Appl Sci Comput"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1128\/JVI.77.14.7945-7956.2003","volume":"77","author":"Basler C.F.","year":"2003","unstructured":"Basler C.F.; Mikulasova A.; Martinez-Sobrido L.; Paragas J.; M\u00fchlberger E.; Bray M.; Klenk H.D.; Palese P.; Garc\u00eda-Sastre A.; The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003,77(14),7945-7956","journal-title":"J Virol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/infdis\/jir359","volume":"204","author":"Reynard O.","year":"2011","unstructured":"Reynard O.; Nemirov K.; Page A.; Mateo M.; Raoul H.; Weissenhorn W.; Volchkov V.E.; Conserved proline-rich re-gion of Ebola virus matrix protein VP40 is essential for plas-ma membrane targeting and virus-like particle release. J Infect Dis 2011,204,884-891","journal-title":"J Infect Dis"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12688\/f1000research.5741.1","volume":"3","author":"Ekins S.","year":"2014","unstructured":"Ekins S.; Freundlich J.S.; Coffee M.; A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000 Res 2014,3,277","journal-title":"F1000 Res"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1016\/j.bmc.2016.08.065","volume":"24","author":"Glanzer J.G.","year":"2016","unstructured":"Glanzer J.G.; Byrne B.M.; McCoy A.M.; James B.J.; Frank J.D.; Oakley G.G.; In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. Bioorg Med Chem 2016,24(21),5388-5392","journal-title":"Bioorg Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biopha.2016.09.034","volume":"84","author":"Ren J.X.","year":"2016","unstructured":"Ren J.X.; Zhang R.T.; Zhang H.; Cao X.S.; Liu L.K.; Xie Y.; Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds. Biomed Pharmacother 2016,84,199-207","journal-title":"Biomed Pharmacother"},{"key":"ref=55","first-page":"1","volume":"2018","author":"Sulaiman K.O.","year":"2018","unstructured":"Sulaiman K.O.; Kolapo T.U.; Onawole A.T.; Islam A.; Adegoke R.O.; Badmus S.O.; Molecular dynamics and com-bined docking studies for the identification of Zaire Ebola Vi-rus inhibitors. J Biomol Struct Dyn 2018,2018,1-31","journal-title":"J Biomol Struct Dyn"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1073\/pnas.0606730104","volume":"104","author":"Hartlieb B.","year":"2007","unstructured":"Hartlieb B.; Muziol T.; Weissenhorn W.; Becker S.; Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc Natl Acad Sci USA 2007,104(2),624-629","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1128\/JVI.02523-06","volume":"81","author":"John S.P.","year":"2007","unstructured":"John S.P.; Wang T.; Steffen S.; Longhi S.; Schmaljohn C.S.; Jonsson C.B.; Ebola virus VP30 is an RNA binding protein. J Virol 2007,81(17),8967-8976","journal-title":"J Virol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"11165","DOI":"10.1074\/jbc.M113.461285","volume":"288","author":"Biedenkopf N.","year":"2013","unstructured":"Biedenkopf N.; Hartlieb B.; Hoenen T.; Becker S.; Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication. J Biol Chem 2013,288(16),11165-11174","journal-title":"J Biol Chem"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1128\/JVI.01395-08","volume":"82","author":"Mart\u00ednez M.J.","year":"2008","unstructured":"Mart\u00ednez M.J.; Biedenkopf N.; Volchkova V.; Hartlieb B.; Alazard-Dany N.; Reynard O.; Becker S.; Volchkov V.; Role of Ebola virus VP30 in transcription reinitiation. J Virol 2008,82(24),12569-12573","journal-title":"J Virol"},{"key":"ref=60","first-page":"1268","volume":"4","author":"Shah R.","year":"2015","unstructured":"Shah R.; Panda P.K.; Patel P.; Panchal H.; Pharmacophore based virtual screening and molecular docking studies of inherited compounds against ebola virus receptor proteins. World J Pharm Pharm Sci 2015,4(5),1268-1282","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12539-016-0149-8","volume":"9","author":"Setlur A.S.","year":"2017","unstructured":"Setlur A.S.; Naik S.Y.; Skariyachan S.; Herbal lead as ideal bioactive compounds against probable drug targets of ebola virus in comparison with known chemical analogue: A computational drug discovery perspective. Interdiscip Sci 2017,9(2),254-277","journal-title":"Interdiscip Sci"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1096\/fasebj.31.1_supplement.945.1","volume":"31","author":"Vecchio K.D.","year":"2017","unstructured":"Vecchio K.D.; Shwarz A.; Saphire E.O.; Stahelin R.; The ebola virus matrix protein vp40 interacts selectively with plasma membrane lipids to promote viral egress. FASEB J 2017,31,945-951","journal-title":"FASEB J"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0969-2126(03)00050-9","volume":"11","author":"Gomis-R\u00fcth F.X.","year":"2003","unstructured":"Gomis-R\u00fcth F.X.; Dessen A.; Timmins J.; Bracher A.; Kolesnikowa L.; Becker S.; Klenk H.D.; Weissenhorn W.; The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure 2003,11(4),423-433","journal-title":"Structure"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1093\/emboj\/19.24.6732","volume":"19","author":"Scianimanico S.","year":"2000","unstructured":"Scianimanico S.; Schoehn G.; Timmins J.; Ruigrok R.H.; Klenk H.D.; Weissenhorn W.; Membrane association induces a conformational change in the Ebola virus matrix protein. EMBO J 2000,19(24),6732-6741","journal-title":"EMBO J"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/ijms17111748","volume":"17","author":"Mirza M.U.","year":"2016","unstructured":"Mirza M.U.; Ikram N.; Integrated computational approach for virtual hit identification against ebola viral proteins VP35 and VP40. Int J Mol Sci 2016,17(11),1748","journal-title":"Int J Mol Sci"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.6026\/97320630012192","volume":"12","author":"M. Alam El-Din","year":"2016","unstructured":"M. Alam El-Din; H.; A Loutfy, S.; Fathy, N.; H Elberry, M.; M Mayla, A.; Kassem, S.; Naqvi, A. Molecular docking based screening of compounds against VP40 from Ebola virus. Bioinformation 2016,12(3),192-196","journal-title":"Bioinformation"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"243","DOI":"10.6026\/97320630011243","volume":"11","author":"Abazari D.","year":"2015","unstructured":"Abazari D.; Moghtadaei M.; Behvarmanesh A.; Ghannadi B.; Aghaei M.; Behruznia M.; Rigi G.; Molecular docking based screening of predicted potential inhibitors for VP40 from Ebola virus. Bioinformation 2015,11(5),243-247","journal-title":"Bioinformation"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40249-016-0105-1","volume":"5","author":"Karthick V.","year":"2016","unstructured":"Karthick V.; Nagasundaram N.; Doss C.G.P.; Chakraborty C.; Siva R.; Lu A.; Zhang G.; Zhu H.; Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus. Infect Dis Poverty 2016,5,12","journal-title":"Infect Dis Poverty"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7897\/2230-8407.04901","volume":"2","author":"Patel J.","year":"2013","unstructured":"Patel J.; Chipkar Y.; Momin A.; Comparitive study of vari-ous ebola virus Vp40 strains with modelling and docking studies to treat ebola virus infection. Intl J Pharm Drug Res 2013,2(1),1-10","journal-title":"Intl J Pharm Drug Res"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1080\/07391102.2015.1094412","volume":"34","author":"Skariyachan S.","year":"2016","unstructured":"Skariyachan S.; Acharya A.B.; Subramaniyan S.; Babu S.; Kulkarni S.; Narayanappa R.; Secondary metabolites extracted from marine sponge associated Comamonas testosteroni and Citrobacter freundii as potential antimicrobials against MDR pathogens and hypothetical leads for VP40 matrix protein of Ebola virus: an in vitro and in silico investigation. J Biomol Struct Dyn 2016,34(9),1865-1883","journal-title":"J Biomol Struct Dyn"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.6026\/97320630009286","volume":"9","author":"Tamilvanan T.","year":"2013","unstructured":"Tamilvanan T.; Hopper W.; High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus. Bioinformation 2013,9(6),286-292","journal-title":"Bioinformation"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1128\/JVI.02349-05","volume":"80","author":"Reid S.P.","year":"2006","unstructured":"Reid S.P.; Leung L.W.; Hartman A.L.; Martinez O.; Shaw M.L.; Carbonnelle C.; Volchkov V.E.; Nichol S.T.; Basler C.F.; Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006,80(11),5156-5167","journal-title":"J Virol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1086\/520582","volume":"196","author":"Watanabe S.","year":"2007","unstructured":"Watanabe S.; Noda T.; Halfmann P.; Jasenosky L.; Kawaoka Y.; Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect Dis 2007,196(Suppl. 2),S284-S290","journal-title":"J Infect Dis"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2010.04.002","volume":"403","author":"Hoenen T.","year":"2010","unstructured":"Hoenen T.; Jung S.; Herwig A.; Groseth A.; Becker S.; Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 2010,403(1),56-66","journal-title":"Virology"},{"key":"ref=75","volume":"1862","author":"Tambunan U.S.F.","year":"2017","unstructured":"Tambunan U.S.F.; Nasution M.A.F.; Identification of novel Ebola virus (EBOV) VP24 inhibitor from Indonesian natural products through in silico drug design approach. AIP Conf Proc 2017,1862(1)","journal-title":"AIP Conf Proc"},{"key":"ref=76","first-page":"59","volume":"15","author":"Tambunan U.S.F.","year":"2018","unstructured":"Tambunan U.S.F.; Siregar S.; Toepak E.P.; Ebola viral protein 24 (Vp24) inhibitor discovery by in silico fragment-based design. Int J Geomech 2018,15(49),59-64","journal-title":"Int J Geomech"},{"key":"ref=77","first-page":"250","volume":"7","author":"Sharmila R.","year":"2016","unstructured":"Sharmila R.; Jaikumar B.; Molecular docking study of bioac-tive compound of andrographolide against ebola virus. Int J Pharm Sci Res 2016,7(5),250-253","journal-title":"Int J Pharm Sci Res"},{"key":"ref=78","first-page":"27","volume":"4","author":"Sharma D.","year":"2017","unstructured":"Sharma D.; Pathak M.; Sharma R.; Tyagi P.; Chawla R.; Basu M.; Ojha H.; Homology modeling and docking studies of VP24 protein of Ebola virus with an antiviral drug and its derivatives. Chem Biol Lett 2017,4(1),27-32","journal-title":"Chem Biol Lett"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s13238-012-2087-5","volume":"3","author":"Sun Y.","year":"2012","unstructured":"Sun Y.; Guo Y.; Lou Z.; A versatile building block: the structures and functions of negative-sense single-stranded RNA virus nucleocapsid proteins. Protein Cell 2012,3(12),893-902","journal-title":"Protein Cell"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tim.2013.07.006","volume":"21","author":"Zhou H.","year":"2013","unstructured":"Zhou H.; Sun Y.; Guo Y.; Lou Z.; Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses. Trends Microbiol 2013,21(9),475-484","journal-title":"Trends Microbiol"},{"key":"ref=81","first-page":"S15","volume":"9","author":"Baikerikar S.","year":"2017","unstructured":"Baikerikar S.; Curcumin and natural derivatives inhibit ebola viral proteins: An in silico approach. Pharmacol Res 2017,9(Suppl. 1),S15-S22","journal-title":"Pharmacol Res"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/prd.12085","volume":"69","author":"Slots J.","year":"2015","unstructured":"Slots J.; Periodontal herpesviruses: prevalence, pathogenicity, systemic risk. Periodontol 2000 2015,69(1),28-45","journal-title":"Periodontol 2000"},{"key":"ref=83","author":"Whitley R.J.","year":"1996","unstructured":"Whitley R.J.; Herpesviruses.University of Texas Medical Branch at Gal-veston; Microbiology, M.; Sam-uel, B., Eds.; Galveston, Texas, 1996"},{"key":"ref=84","first-page":"2","author":"Robbins G.","year":"2015","unstructured":"Robbins G.; Lammert S.; Rompalo A.; Riley L.; Daskalakis D.; Morrow R.; Lee H.; Shui A.; Gaydos C.; Detrick B.; Rosenber E.; Crochiere D.; Cunningham K.; Bradley H.; Markowitz L.; Xu F.; Felsenstein D.; Serologic assays for the diagnosis of herpes virus 1 (HSV-1) herpes virus 2 (HSV-2): test characteristics of FDA approved type-specific assays in an ethnically, racially, and economi-cally diverse patient population. Open Forum Infectious Diseases 2015,2","journal-title":"Open Forum Infectious Diseases"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.29687","volume":"138","author":"Rohner E.","year":"2016","unstructured":"Rohner E.; Wyss N.; Heg Z.; Faralli Z.; Mbulaiteye S.M.; Novak U.; Zwahlen M.; Egger M.; Bohlius J.; HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. Int J Cancer 2016,138(1),45-54","journal-title":"Int J Cancer"},{"key":"ref=86","year":"2017","unstructured":"World Health Organization: Herpes simplex virus (Accessed Oct 2, 2018)2017","journal-title":"Herpes simplex virus"},{"key":"ref=87","first-page":"754","volume":"217","author":"Burn C.","year":"2018","unstructured":"Burn C.; Ramsey N.; Garforth S.J.; Almo S.; Jacobs W.R.; Herold B.C.; A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2. J Infect Dis 2018,217(5),754-758","journal-title":"J Infect Dis"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1638\/2016-0141R1.1","volume":"48","author":"Sripiboon S.","year":"2017","unstructured":"Sripiboon S.; Angkawanish T.; Boonprasert K.; Sombutputorn P.; Langkaphin W.; Ditcham W.; Warren K.; Successful treatment of a clinical elephant endotheliotropic herpesvirus infection: The dynamics of viral load, genotype analysis, and treatment with acyclovir. J Zoo Wildl Med 2017,48(4),1254-1259","journal-title":"J Zoo Wildl Med"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/jfd.12880","volume":"41","author":"Troszok A.","year":"2018","unstructured":"Troszok A.; Kolek L.; Szczygie\u0142 J.; Wawrzeczko J.; Borzym E.; Reichert M.; Kami\u0144ska T.; Ostrowski T.; Jurecka P.; Adamek M.; Rakus K.; Irnazarow I.; Acyclovir inhibits Cyprinid herpesvirus 3 multiplication in vitro. J Fish Dis 2018,41(11),1709-1718","journal-title":"J Fish Dis"},{"key":"ref=90","first-page":"1185","author":"Piret J.","year":"2017","unstructured":"Piret J.; Boivin G.; Herpesvirus Resistance to Antiviral Drugs 2017,1185-1211","journal-title":"Herpesvirus Resistance to Antiviral Drugs"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1128\/JVI.00416-15","volume":"89","author":"Kolb A.W.","year":"2015","unstructured":"Kolb A.W.; Larsen I.V.; Cuellar J.A.; Brandt C.R.; Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. J Virol 2015,89(12),6427-6434","journal-title":"J Virol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.1074\/jbc.274.40.28059","volume":"274","author":"Lehman I.R.","year":"1999","unstructured":"Lehman I.R.; Boehmer P.E.; Replication of herpes simplex virus DNA. J Biol Chem 1999,274(40),28059-28062","journal-title":"J Biol Chem"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0166-3542(93)90001-Y","volume":"20","author":"Matthews J.T.","year":"1993","unstructured":"Matthews J.T.; Terry B.J.; Field A.K.; The structure and function of the HSV DNA replication proteins: Defining novel antiviral targets. Antiviral Res 1993,20(2),89-114","journal-title":"Antiviral Res"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"14023","DOI":"10.1021\/bi9712697","volume":"36","author":"Hoog S.S.","year":"1997","unstructured":"Hoog S.S.; Smith W.W.; Qiu X.; Janson C.A.; Hellmig B.; McQueney M.S.; O\u2019Donnell K.; O\u2019Shannessy D.; DiLella A.G.; Debouck C.; Abdel-Meguid S.S.; Active site cavity of herpesvirus proteases revealed by the crystal structure of herpes simplex virus protease\/inhibitor complex. Biochemistry 1997,36(46),14023-14029","journal-title":"Biochemistry"},{"key":"ref=95","first-page":"411","author":"Kashyap K.","year":"2017","unstructured":"Kashyap K.; Kakkar R.; Herpesvirus Proteases: Structure, Function, and Inhibition 2017,411-439","journal-title":"Herpesvirus Proteases: Structure, Function, and Inhibition"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.micpath.2018.03.052","volume":"118","author":"Arunkumar J.","year":"2018","unstructured":"Arunkumar J.; Rajarajan S.; Study on antiviral activities, drug-likeness and molecular docking of bioactive compounds of Punica granatum L. to Herpes simplex virus - 2 (HSV-2). Microb Pathog 2018,118,301-309","journal-title":"Microb Pathog"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nsmb.1837","volume":"17","author":"Chowdary T.K.","year":"2010","unstructured":"Chowdary T.K.; Cairns T.M.; Atanasiu D.; Cohen G.H.; Eisenberg R.J.; Heldwein E.E.; Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 2010,17(7),882-888","journal-title":"Nat Struct Mol Biol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1128\/mBio.00046-13","volume":"4","author":"Atanasiu D.","year":"2013","unstructured":"Atanasiu D.; Cairns T.M.; Whitbeck J.C.; Saw W.T.; Rao S.; Eisenberg R.J.; Cohen G.H.; Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH\/gL in the absence of gD and cellular receptors. MBio 2013,4(2),e00046-e13","journal-title":"MBio"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrmicro2548","volume":"9","author":"Connolly C.S.A.","year":"2011","unstructured":"Connolly C.S.A.; Jackson J.O.; Jardetzky T.S.; Longnecker R.; Fusing structure and function: a structural view of the her-pesvirus entry machinery. Nat Rev Microbiol 2011,9(5),369","journal-title":"Nat Rev Microbiol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10900-016-0234-2","volume":"42","author":"Boyer C.B.","year":"2017","unstructured":"Boyer C.B.; Greenberg L.; Chutuape K.; Walker B.; Monte D.; Kirk J.; Ellen J.M.; Belzer M.; Martinez M.; Dudek J.; Adolescent medicine trials network. exchange of sex for drugs or money in adolescents and young adults: An examination of sociodemographic factors, HIV-related risk, and community context. J Commun Healthc 2017,42(1),90-100","journal-title":"J Commun Healthc"},{"key":"ref=101","first-page":"1108","volume":"25","author":"Strategies P.","year":"2002","unstructured":"Strategies P.; Therapy F.O.R.A.; Tecnol D.; Cruz O.; Estrat\u00e9gias farmacol\u00f3gicas para a terapia anti-aids Emerson Poley Pe\u00e7anha* e Octavio A. C. Antunes 2002,25(6),1108-1116","journal-title":"Antunes"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1145\/3233547.3233596","author":"Morris P.","year":"2018","unstructured":"Morris P.; DaSilva Y.; Clark E.; Hahn W.E.; Barenholtz E.; Convolutional Neural Networks for Predicting Molecular Binding Affinity to HIV-1 Proteins. ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (BCB \u201918) ACM, New York, NY, USA, 2018,220-225","journal-title":"ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (BCB \u201918)"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molstruc.2017.03.029","volume":"1139","author":"Mohammadi A.A.","year":"2017","unstructured":"Mohammadi A.A.; Taheri S.; Amouzegar A.; Ahdenov R.; Halvagar M.R.; Sadr A.S.; Diastereoselective synthesis and molecular docking studies of novel fused tetrahydro-pyridine derivatives as new inhibitors of HIV protease. J Mol Struct 2017,1139,166-174","journal-title":"J Mol Struct"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molstruc.2016.09.052","volume":"1129","author":"Tong J.","year":"2017","unstructured":"Tong J.; Wu Y.; Bai M.; Zhan P.; 3D-QSAR and molecular docking studies on HIV protease inhibitors. J Mol Struct 2017,1129,17-22","journal-title":"J Mol Struct"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmgm.2018.03.006","volume":"82","author":"Zondagh J.","year":"2018","unstructured":"Zondagh J.; Balakrishnan V.; Achilonu I.; Dirr H.W.; Sayed Y.; Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease. J Mol Graph Model 2018,82,1-11","journal-title":"J Mol Graph Model"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1038\/s41598-018-22485-5","volume":"8","author":"Ahmad R.","year":"2018","unstructured":"Ahmad R.; Sahidin I.; Taher M.; Low C.; Noor N.M.; Sillapachaiyaporn C.; Chuchawankul S.; Sarachana T.; Tencomnao T.; Iskandar F.; Rajab N.F.; Baharum S.N.; Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities. Sci Rep 2018,8(1),4202","journal-title":"Sci Rep"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molstruc.2017.04.070","volume":"1143","author":"Al-Shehri M.M.","year":"2017","unstructured":"Al-Shehri M.M.; Al-Majed A.R.A.; Aljohar H.I.; El-Emam A.A.; Pathak S.K.; Sachan A.K.; Prasad O.; Sinha L.; First principle study of a potential bioactive molecule with tetrahydroisoquinoline, carbothiomide and adamantane scaffolds. J Mol Struct 2017,1143,204-216","journal-title":"J Mol Struct"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1021\/acs.jmedchem.6b00639","volume":"59","author":"Ghosh A.K.","year":"2016","unstructured":"Ghosh A.K.; Osswald H.L.; Glauninger K.; Agniswamy J.; Wang Y-F.; Hayashi H.; Aoki M.; Weber I.T.; Mitsuya H.; Probing lipophilic adamantyl group as the P1-ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation. J Med Chem 2016,59(14),6826-6837","journal-title":"J Med Chem"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/cbdd.12974","volume":"90","author":"Debnath U.","year":"2017","unstructured":"Debnath U.; Kumar P.; Agarwal A.; Kesharwani A.; Gupta S.K.; Katti S.B.; N-hydroxy-substituted 2-aryl acetamide analogs: A novel class of HIV-1 integrase inhibitors. Chem Biol Drug Des 2017,90(4),527-534","journal-title":"Chem Biol Drug Des"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00044-016-1772-y","volume":"26","author":"Vyas V.K.","year":"2017","unstructured":"Vyas V.K.; Shah S.; Ghate M.; Generation of new leads as HIV-1 integrase inhibitors: 3D QSAR, docking and molecular dynamics simulation. Med Chem Res 2017,26(3),532-550","journal-title":"Med Chem Res"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/1386207320666170615104703","volume":"20","author":"Chander S.","year":"2017","unstructured":"Chander S.; Pandey R.K.; Penta A.; Choudhary B.S.; Sharma M.; Malik R.; Prajapati V.K.; Murugesan S.; Molecular docking and molecular dynamics simulation based approach to explore the dual inhibitor against HIV-1 reverse transcriptase and integrase. Comb Chem High Throughput Screen 2017,20(8),734-746","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bmcl.2018.02.020","volume":"28","year":"2018","unstructured":"Faridoon; Mnkandhla, D.; Isaacs, M.; Hoppe, H. C.; Kaye, P. T. Synthesis and evaluation of substituted 4-arylimino-3-hydroxybutanoic acids as potential HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2018,28(6),1067-1070","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejmech.2016.10.045","volume":"125","author":"Zhang F.H.","year":"2017","unstructured":"Zhang F.H.; Debnath B.; Xu Z.L.; Yang L.M.; Song L.R.; Zheng Y.T.; Neamati N.; Long Y.Q.; Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF\/p75 interaction. Eur J Med Chem 2017,125,1051-1063","journal-title":"Eur J Med Chem"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1080\/07391102.2017.1384400","volume":"36","author":"Panwar U.","year":"2018","unstructured":"Panwar U.; Singh S.K.; Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and hu-man lens epithelium-derived growth factor (LEDGF\/P75). J Biomol Struct Dyn 2018,36(12),3199-3217","journal-title":"J Biomol Struct Dyn"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"S1081","DOI":"10.1016\/j.arabjc.2013.01.015","volume":"10","author":"Srivastav V.K.","year":"2017","unstructured":"Srivastav V.K.; Tiwari M.; QSAR and Docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors. Arab J Chem 2017,10,S1081-S1094","journal-title":"Arab J Chem"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1021\/acs.jcim.7b00153","volume":"57","author":"Ericksen S.S.","year":"2017","unstructured":"Ericksen S.S.; Wu H.; Zhang H.; Michael L.A.; Newton M.A.; Hoffmann F.M.; Wildman S.A.; Machine learning consensus scoring improves performance across targets in structure-based virtual screening. J Chem Inf Model 2017,57(7),1579-1590","journal-title":"J Chem Inf Model"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejmech.2018.01.016","volume":"145","author":"Jin K.","year":"2018","unstructured":"Jin K.; Yin H.; De Clercq E.; Pannecouque C.; Meng G.; Chen F.; Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. Eur J Med Chem 2018,145,726-734","journal-title":"Eur J Med Chem"},{"key":"ref=118","first-page":"870","volume":"57","author":"Kashid A.M.","year":"2018","unstructured":"Kashid A.M.; Dhawale S.; Design, Synthesis and Biological Screening of N 1 - (Substituted Pyridine-2-Yl) -N 3 - (Quinoline-2-Yl). Malonamide as Novel Anti-HIV-I Agents., Ind. J. Chem. Sec. B Org. Med Chem 2018,57,870-879","journal-title":"Med Chem"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/ijms19051436","volume":"19","author":"Liu G.","year":"2018","unstructured":"Liu G.; Wang W.; Wan Y.; Ju X.; Gu S.; Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molec-ular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors. Int J Mol Sci 2018,19(5),1436","journal-title":"Int J Mol Sci"},{"key":"ref=120","first-page":"37","volume":"147","author":"Singh A.","year":"2018","unstructured":"Singh A.; Singh V.K.; Verma R.; Singh R.K.; In Silico Studies on N - (Pyridin- 2-Yl) Thiobenzamides as NNRTIs against Wild and Mutant HIV-1 Strains. Philipp J Sci 2018,147(March),37-46","journal-title":"Philipp J Sci"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11224-018-1082-8","volume":"29","author":"Peddi S.R.","year":"2018","unstructured":"Peddi S.R.; Mohammed N.A.; Hussein A.A.; Sivan S.K.; Manga V.; Multiple-Receptor Conformation Docking, Dock Pose Clustering, and 3D QSAR-Driven Approaches Exploring New HIV-1 RT Inhibitors. Struct Chem 2018,29(4),999-1012","journal-title":"Struct Chem"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejmech.2017.02.047","volume":"130","author":"Zhang H.","year":"2017","unstructured":"Zhang H.; Tian Y.; Kang D.; Huo Z.; Zhou Z.; Liu H.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X.; Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. Eur J Med Chem 2017,130,209-222","journal-title":"Eur J Med Chem"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jmgm.2017.06.011","volume":"75","author":"Samanta P.N.","year":"2017","unstructured":"Samanta P.N.; Das K.K.; Inhibition activities of catechol diether based non-nucleoside inhibitors against the HIV reverse transcriptase variants: Insights from molecular docking and ONIOM calculations. J Mol Graph Model 2017,75,294-305","journal-title":"J Mol Graph Model"},{"key":"ref=124","first-page":"1","volume":"8","author":"Poongavanam V.","year":"2018","unstructured":"Poongavanam V.; Namasivayam V.; Vanangamudi M.; Al Shamaileh H.; Veedu R.N.; Kihlberg J.; Murugan N.A.; In-tegrative Approaches in HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Design. Wiley Interdiscip Rev Comput Mol Sci 2018,8(1),1-26","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.bmc.2017.12.033","volume":"26","author":"Monforte A.M.","year":"2018","unstructured":"Monforte A.M.; De Luca L.; Buemi M.R.; Agharbaoui F.E.; Pannecouque C.; Ferro S.; Structural optimization of N-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem 2018,26(3),661-674","journal-title":"Bioorg Med Chem"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/cmb.2018.81001","volume":"8","author":"Cabrera A.","year":"2018","unstructured":"Cabrera A.; Huerta H.L.; Ch\u00e1vez D.; Medina-Franco J.L.; Molecular Modeling of Potential Dual Inhibitors of HIV Reverse Transcriptase and Integrase. Comput Mol Biosci 2018,8,1-41","journal-title":"Comput Mol Biosci"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejmech.2017.03.059","volume":"133","author":"Tang J.","year":"2017","unstructured":"Tang J.; Vernekar S.K.V.; Chen Y.L.; Miller L.; Huber A.D.; Myshakina N.; Sarafianos S.G.; Parniak M.A.; Wang Z.; Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. Eur J Med Chem 2017,133,85-96","journal-title":"Eur J Med Chem"},{"key":"ref=128","first-page":"129","volume":"1","author":"Barberato C.","year":"2018","unstructured":"Barberato C.; Neto Z.G.; A A\u00c7\u00c3O coletiva como instrumento de tutela e concretiza\u00e7\u00e3o do direito \u00e0 sa\u00fade. J Popul 2018,1(3),129-146","journal-title":"J Popul"},{"key":"ref=129","first-page":"73","volume":"81","author":"Sousa S.J.F.E.","year":"2018","unstructured":"Sousa S.J.F.E.; Sousa S.B.F.E.; Eye bank procedures: donor selection criteria. Arq Bras Oftalmol 2018,81(1),73-79","journal-title":"Arq Bras Oftalmol"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"pii. A031823.","DOI":"10.1101\/cshperspect.a031823","volume":"9","author":"Lemon S.M.","year":"2019","unstructured":"Lemon S.M.; Walker C.M.; Hepatitis A.; Virus and Hepatitis E Virus: Emerging and Re-Emerging Enterically Transmitted Hepatitis Viruses. Cold Spring Harb Perspect Med, 2019,9(6),pii. A031823.","journal-title":"Cold Spring Harb Perspect Med,"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1358\/dof.2016.041.02.2382555","volume":"41","author":"Majumdar A.","year":"2016","unstructured":"Majumdar A.; Gilliam B.L.; Arnold R.; Rock C.; Croft L.; Morgan D.J.; Donnenberg M.S.; Majid A.; McAninch J.; Morgan D.J.; Grazoprevir Potassium. HCV NS3 NS4A Prote-ase Inhibitor, Anti-Hepatitis C Virus Drug. Drugs Future 2016,41(2),85-109","journal-title":"Drugs Future"},{"key":"ref=132","author":"Pontarolo R.","year":"2017","unstructured":"Pontarolo R.; Borba H.H.L.; Ferreira V.L.; Pedroso M.L.A.; Souza A.W.; Siqueira F.M.; Direct-Acting Antivirals For Chronic Hepatitis C Treatment, ed. Berlin, Germany: Arid Science, v., p.t.2017"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"Stanaway J.D.","year":"2016","unstructured":"Stanaway J.D.; Flaxman A.D.; Naghavi M.; Fitzmaurice C.; Vos T.; Abubakar I.; Abu-Raddad L.J.; Assadi R.; Bhala N.; Cowie B.; Forouzanfour M.H.; Groeger J.; Hanafiah K.M.; Jacobsen K.H.; James S.L.; MacLachlan J.; Malekzadeh R.; Martin N.K.; Mokdad A.A.; Mokdad A.H.; Murray C.J.L.; Plass D.; Rana S.; Rein D.B.; Richardus J.H.; Sanabria J.; Saylan M.; Shahraz S.; So S.; Vlassov V.V.; Weiderpass E.; Wiersma S.T.; Younis M.; Yu C.; El Sayed Zaki M.; Cooke G.S.; The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016,388(10049),1081-1088","journal-title":"Lancet"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"Liver E.A.F.T.S.O.T.","year":"2017","unstructured":"Liver E.A.F.T.S.O.T.; EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017,67(2),370-398","journal-title":"J Hepatol"},{"key":"ref=135","doi-asserted-by":"crossref","DOI":"10.1542\/9781581109276","author":"Kimberlin D.W.","year":"2015","unstructured":"Kimberlin D.W.; Brady M.T.; Jackson M.A.; Long S.S.; Red Book: 2015 Report of the Committee on Infec-tious Diseases 2015","journal-title":"Red Book: 2015 Report of the Committee on Infec-tious Diseases"},{"key":"ref=136","author":"Giesecke J.","year":"2017","unstructured":"Giesecke J.; Modern Infectious Disease Epidemiology 2017","journal-title":"Modern Infectious Disease Epidemiology"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","volume":"59","author":"Pilot-Matias T.","year":"2015","unstructured":"Pilot-Matias T.; Tripathi R.; Cohen D.; Gaultier I.; Dekhtyar T.; Lu L.; Reisch T.; Irvin M.; Hopkins T.; Pithawalla R.; Middleton T.; Ng T.; McDaniel K.; Or Y.S.; Menon R.; Kempf D.; Molla A.; Collins C.; In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 2015,59(2),988-997","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12558","volume":"180","author":"Foureau D.M.","year":"2015","unstructured":"Foureau D.M.; Walling T.L.; Maddukuri V.; Anderson W.; Culbreath K.; Kleiner D.E.; Ahrens W.A.; Jacobs C.; Watkins P.B.; Fontana R.J.; Chalasani N.; Talwalkar J.; Lee W.M.; Stolz A.; Serrano J.; Bonkovsky H.L.; Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015,180(1),40-51","journal-title":"Clin Exp Immunol"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","volume":"116","author":"Sarrazin C.","year":"2015","unstructured":"Sarrazin C.; Lathouwers E.; Peeters M.; Daems B.; Buelens A.; Witek J.; Wyckmans Y.; Fevery B.; Verbinnen T.; Ghys A.; Schlag M.; Baldini A.; De Meyer S.; Lenz O.; Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015,116,10-16","journal-title":"Antiviral Res"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","volume":"347","author":"Appleby T.C.","year":"2015","unstructured":"Appleby T.C.; Perry J.K.; Murakami E.; Barauskas O.; Feng J.; Cho A.; Fox D.; Wetmore D.R.; McGrath M.E.; Ray A.S.; Structural Basis for RNA Replication by the Hepatitis C Virus Polymerase. Science 2015,347(6223),771-775","journal-title":"Science"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/ci700266z","volume":"48","author":"Patel P.D.","year":"2008","unstructured":"Patel P.D.; Patel M.R.; Kaushik-Basu N.; Talele T.T.; 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model 2008,48(1),42-55","journal-title":"J Chem Inf Model"},{"key":"ref=142","first-page":"683","volume":"4","author":"Vani G.S.","year":"2015","unstructured":"Vani G.S.; Rajarajan S.; A Study on In-Silico Analysis of Phytochemicals Targeting the Proteins of Hepatitis B and C Virus. Int J Curr Microbiol Appl Sci 2015,4(12),683-691","journal-title":"Int J Curr Microbiol Appl Sci"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.2174\/092986710791859298","volume":"17","author":"Wang X.","year":"2010","unstructured":"Wang X.; Yang W.; Xu X.; Zhang H.; Li Y.; Wang Y.; Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr Med Chem 2010,17(25),2788-2803","journal-title":"Curr Med Chem"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"49","DOI":"10.12970\/2308-8044.2015.03.02.2","volume":"3","author":"Anithaa K.","year":"2015","unstructured":"Anithaa K.; Singhb N.; Shaikc B.; Ahmadc I.; Agrawald V.K.; Guptac S.P.; QSAR and Docking Studies on 1, 1-Dioxo-2H-Benzothiadiazines Acting as HCV NS5B Polymerase In-hibitors. J Mod Med Chem 2015,3,49-68","journal-title":"J Mod Med Chem"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejmech.2012.03.002","volume":"52","author":"Liu M-M.","year":"2012","unstructured":"Liu M-M.; Zhou L.; He P-L.; Zhang Y-N.; Zhou J-Y.; Shen Q.; Chen X-W.; Zuo J-P.; Li W.; Ye D-Y.; Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. Eur J Med Chem 2012,52,33-43","journal-title":"Eur J Med Chem"},{"key":"ref=146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005297","volume":"11","author":"Scull M.A.","year":"2015","unstructured":"Scull M.A.; Schneider W.M.; Flatley B.R.; Hayden R.; Fung C.; Jones C.T.; van de Belt M.; Penin F.; Rice C.M.; The N-terminal Helical Region of the Hepatitis C Virus p7 Ion Channel Protein Is Critical for Infectious Virus Production. PLoS Pathog 2015,11(11)","journal-title":"PLoS Pathog"},{"key":"ref=147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006863","volume":"14","author":"Boukadida C.","year":"2018","unstructured":"Boukadida C.; Fritz M.; Blumen B.; Fogeron M-L.; Penin F.; Martin A.; NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities. PLoS Pathog 2018,14(2)","journal-title":"PLoS Pathog"},{"key":"ref=148","first-page":"S686","volume":"Vol. 62","author":"Lisboa Neto G.","year":"2015","unstructured":"Lisboa Neto G.; Noble C.; Pinho J.R.R.; Malta F.M.; Gomes-Gouvea M.S.; Alvarado-Mora M.V.; Silva M.H.; Leite A.G.; Piccoli L.Z.; Carrilho F.J.; Characterization of clinical predictors of naturally oc-curring ns3\/ns4a protease polymorphism in genotype 1 hepatitis c virus infected patients J Hepatol 2015,Vol. 62,S686-S686","journal-title":"Characterization of clinical predictors of naturally oc-curring ns3\/ns4a protease polymorphism in genotype 1 hepatitis c virus infected patients J Hepatol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1016\/j.bmcl.2013.05.046","volume":"23","author":"Bailey M.D.","year":"2013","unstructured":"Bailey M.D.; Halmos T.; Lemke C.T.; Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett 2013,23(15),4436-4440","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=150","first-page":"1","volume":"17","author":"Wei Y.","year":"2018","unstructured":"Wei Y.; Yang J.; Kishore Sakharkar M.; Wang X.; Liu Q.; Du J.; Zhang J-J.; Evaluating the Inhibitory Effect of Eight Compounds from Daphne Papyracea against the NS3\/4A Pro-tease of Hepatitis C Virus. Nat Prod Res 2018,17,1-4","journal-title":"Nat Prod Res"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1080\/14786419.2015.1075527","volume":"30","author":"Ashfaq U.A.","year":"2016","unstructured":"Ashfaq U.A.; Jalil A.; Ul Qamar M.T.; Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach. Nat Prod Res 2016,30(16),1866-1869","journal-title":"Nat Prod Res"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.antiviral.2015.10.001","volume":"124","author":"Shaw J.","year":"2015","unstructured":"Shaw J.; Harris M.; Fishwick C.W.G.; Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease. Antiviral Res 2015,124,54-60","journal-title":"Antiviral Res"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14786419.2015.1020490","volume":"30","author":"Lulu S.S.","year":"2016","unstructured":"Lulu S.S.; Thabitha A.; Vino S.; Priya A.M.; Rout M.; Naringenin and quercetin--potential anti-HCV agents for NS2 protease targets. Nat Prod Res 2016,30(4),464-468","journal-title":"Nat Prod Res"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/cbdd.13329","volume":"92","author":"Uddin R.","year":"2018","unstructured":"Uddin R.; Downard K.M.; Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein. Chem Biol Drug Des 2018,92(3),1638-1646","journal-title":"Chem Biol Drug Des"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.phymed.2018.09.025","volume":"53","author":"Hung T-C.","year":"2019","unstructured":"Hung T-C.; Jassey A.; Liu C-H.; Lin C-J.; Lin C-C.; Wong S.H.; Wang J.Y.; Yen M-H.; Lin L-T.; Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. Phytomedicine 2019,53,62-69","journal-title":"Phytomedicine"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:47:03Z","timestamp":1721065623000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170612\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":155,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203720666190311142747","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}